NASDAQ: ACADAcadia Pharmaceuticals Inc Stock
$16.07-0.15 (-0.92%)
Updated Sep 6, 2024
ACAD Price
$16.07
Fair Value Price
N/A
Market Cap
$2.67B
52 Week Low
$14.55
52 Week High
$32.59
P/E
89.28x
P/B
5.16x
P/S
3.02x
PEG
0.93x
Dividend Yield
N/A
Revenue
$890.53M
Earnings
$30.57M
Gross Margin
91.7%
Operating Margin
5.14%
Profit Margin
3.4%
Debt to Equity
0.77
Operating Cash Flow
$81M
Beta
0.86
Next Earnings
Oct 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ACAD Overview
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACAD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACAD ($16.07) is trading above its intrinsic value of $7.03, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ACAD is poor value based on its earnings relative to its share price (89.28x), compared to the US market average (24.57x)
P/E vs Market Valuation
ACAD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ACAD due diligence checks available for Premium users.
Be the first to know about important ACAD news, forecast changes, insider trades & much more!
ACAD News
Valuation
ACAD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
89.28x
Industry
-46.85x
Market
24.57x
ACAD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ACAD is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ACAD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.16x
Industry
6.22x
ACAD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACAD price to earnings growth (PEG)
For valuing profitable companies with growth potential
ACAD is good value based... subscribe to Premium to read more.
PEG Value Valuation
ACAD's financial health
Profit margin
Revenue
$242.0M
Net Income
$33.4M
Profit Margin
13.8%
ACAD's Earnings (EBIT) of $45.74M... subscribe to Premium to read more.
Interest Coverage Financials
ACAD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$914.1M
Liabilities
$397.4M
Debt to equity
0.77
ACAD's short-term assets ($728.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACAD's short-term assets ($728.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACAD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACAD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$25.0M
Investing
-$56.2M
Financing
$3.6M
ACAD's operating cash flow ($80.53M)... subscribe to Premium to read more.
Debt Coverage Financials
ACAD vs Biotech Stocks
Acadia Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.